Hema Now
In this episode of Hema Now, Anna Schuh discusses the evolution of precision medicine in haematology. From her early inspiration to pursue haematology to her pioneering work in chronic lymphocytic leukaemia, she reflects on how whole genome sequencing, single-cell technologies, and circulating tumour DNA are transforming risk prediction and treatment strategies.
Spotify | Apple | Amazon Music | YouTube | Download MP3 (39 mins)
Anna Schuh is a Professor and Director of Molecular Diagnostics at the University of Oxford; and an Honorary Consultant Haematologist at Oxford University Hospitals, UK. She completed her academic and clinical haematology training in Oxford, UK, and is internationally recognised for her work in chronic lymphocytic leukaemia, molecular diagnostics, and precision cancer medicine. Schuh has played a pivotal role in global haematology initiatives, including National Institute for Health and Care Research (NIHR)-funded programmes in East Africa, and is Founder and Clinical Director of the Oxford Molecular Diagnostics Centre, UK.
Timestamps:
00:00 – Introduction
02:20 – What drew Anna to haematology
03:57 – Chronic lymphocytic leukaemia
08:55 – Genomics reshaping high risk chronic lymphocytic leukaemia
12:19 – OxPLoreD and STELLAR aims
15:52 – Liquid biopsies
19:56 – Global diagnostics implementation challenges
25:57 – Integrating molecular testing clinically
29:20 – Training future precision leaders
33:51 – Next breakthroughs in precision haematology
35:35 – Three magic wishes
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
